Condition
HER2 Positive Solid Tumor
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Recruiting1
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07631871Phase 2Not Yet Recruiting
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
NCT07009184Early Phase 1RecruitingPrimary
TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.
NCT04040699Phase 1CompletedPrimary
KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor
Showing all 3 trials